Vanguard Global Advisers
CRDF icon

Vanguard Global Advisers’s Cardiff Oncology CRDF Stock Holding History

Vanguard Global Advisers’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9K Hold
25,271
– – ﹤0.01% 3203
2026
Q1 		$40.9K Buy
+25,271
New +$51.9K ﹤0.01% 3103

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Global Advisers's CRDF Position: Q2 2026 in Review

Vanguard Global Advisers held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 25,271 shares worth $32.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3203.

Vanguard Global Advisers first reported a position in CRDF in Q1 2026 and has held it in 2 quarters since. The position peaked at $40.9K in Q1 2026. 104 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Vanguard Global Advisers held 25,271 shares of Cardiff Oncology worth $32.9K as of Q2 2026.
  • Vanguard Global Advisers left its Cardiff Oncology share count unchanged in Q2 2026.
  • Cardiff Oncology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3203 holding.
  • Vanguard Global Advisers first reported a position in Cardiff Oncology in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Cardiff Oncology position peaked at $40.9K in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.